This document summarizes a new porous titanium dental implant technology called Ti FoamTM that is created using nanotechnology. It has the following key advantages over other dental implants: 1) Its porous structure mimics bone to facilitate rapid bone growth; 2) Growth enhancers and antibiotics embedded in the material promote even faster healing within days rather than months; 3) The expanded surface area of the porous material allows it to bond twice as much bone. This positioning opens opportunities in a large and growing $3.5 billion global dental implant market. The technology has completed development and testing and seeks $1.5 million in initial funding to commercialize the product.

1. EVOLUTION of
DENTAL IMPLANTS
The
February 2014

2. Ti Foam™ is a porous titanium
nanotechnology dental implant
that is created by a joint research
and development project by
National Research Council of
Canada Industrial Materials
Institute a Canadian government
supported SME incubator system
in conjunction with
Dr. Mislav Pavelic
Founder/CEO, DDS, FICOI
25 years of Industry experience
with over 10,000 real world
surgeries
2 previous successful start-ups
with industry buyouts
2/11/2014
Open Cell BioMed Merging Proprietary
Biomedical Materials with Human Cell Biology
2

3. 2/11/2014
Open Cell BioMed Merging Proprietary
Biomedical Materials with Human Cell
Biology
3

4. Opencell’s
Healing
times
reduced
MONTHS
DAYS
Candidates
2X
with poor bone
increased
candidate pool
2/11/2014
Technology
Structure mimics bone
(the scaffold) +
(molecular enhancer)
Nanotechnology = 3D
super charged bone
growth bone growth
Open Cell BioMed Merging Proprietary
Biomedical Materials with Human Cell Biology
4

5. BIOMIMETIC SCAFFOLD
High porosity (70%-85%)
Permeability (i.e. pore size
between 50-400 µm)
Foaming creates 20X the
surface area for attachment
BONE
Structures and properties
mimic those of Trabecular
bone facilitating bone
growth and grafting
Open Cell BioMed Merging Proprietary Biomedical Materials with Human Cell Biology
2/11/2014
5

6. BONE MORPHOGENIC PROTEINS
(BMP-2) INCREASE OSTEOBLAST
PROLIFERATION
IMBEDDING ANTIBIOTICS
(FLAGYL®
METRONIDAZOLE)
DRASTICALLY REDUCING
RISK OF INFECTION
Nano surface modifier's of the
Ti Foam™ porous titanium
scaffold; etching
processes, hydrophilic
agents, ionizers, hydroxyl
apatite's and phosphates Cell BioMed Merging Proprietary
Open
= super charged
bone growth
2/11/2014
Biomedical Materials with Human Cell
Biology
6

7. Video showing 3-Dimensional growth of Bone into Ti Foam™
http://www.youtube.com/watch?v=hdsc
nna5r1Q
2/11/2014
Open Cell BioMed Merging Proprietary
Biomedical Materials with Human Cell
Biology
8

8. 
The Opportunity

Dental Implant Market

$3.5 BILLION



High growth market over the
period 2010–2017, rising from $2.6
billion in 2010 to about $5 billion
in 2017,
aging population ,
emerging markets are currently only
a bleep in this market
Noble, Straumann, Biomet, and
Zimmer are all Billion dollar
companies
Numerous dental implant
companies – market is primed for
M&A activity
In 2010, Danaher purchase of Implant
Direct, an innovative fast-growing dental
implant company founded in 2004. The
value of the deal was $240 mil , or 4x
sales.
Open
2/11/2014 Cell BioMed Merging Proprietary Biomedical Materials with Human Cell Biology
9

9. Competition / Customer / Acquirer
Company
Worldwide % of
Implant Market
20
20
19
9
8
Other
24
In 2012, Zimmer Dental
Inc., announced the launch of
their Trabecular Metal Dental
Implant (a product similar to TiFOAM – but not titanium) in the
U.S. and select global markets.
While segmented numbers are
not available for this particular
product, the company has said
that sales growth has been
strong. This product uses a
different manufacturing process
and does not incorporate
nanotech growth inducers or
antibiotics.
The EVOLUTION of

10. 2/11/2014
Merging Proprietary Biomedical Materials with
Human Cell Biology
1.
Proprietary Technology – Strong IP -the foaming process is
developed by National Research Council of Canada Industrial Materials Institute
and exclusively licensed to our company for the use on dental implants.
Additionally the company has patents pending on the manufacturing process for
a Titanium foamed surface coated dental implant and a fully Titanium foamed
dental implant as well as design patents for a Titanium foamed surface coated
dental implant and a fully Titanium foamed dental implant.
2.
Process and design –2 Other companies (Biomet-3i and Zimmer) have
porous titanium from other manufacturing processes (chemical treatments)but
have not been able to utilize it on a dental implant design
3.
Strategic Partnerships – Our strategic relationships with National
Research Council of Canada Industrial Materials Institute and participating
universities build barriers of entry for our competition
4.
Proprietary Surgical Technique - Bone Graft Surface Impaction
Technique®
5.
Low Regulatory Risk – Class 2 Medical Device – gets to market
quickly
11

11. 2/11/2014
Completed Stage 4 in our R&D project
namely FDA 510K requirements
1-Development and optimization of the design
2-Validation of the performances
(structure, microstructure, composition, implantation, Fatigue
Testing ISO14801 Testing completed- Results show the foam
holds up to and beyond the forces of mastication*
3-Optimization of the fabrication process

The project cost 1 million to complete with $500,000.00 in
seed capital from the principal and The Canadian
Government contributed its facilities and Labour force to
the tune of $500,000.

The company is now ready to commercialise its unique first
product line of Ti Foam™ nanotechnology coated
threaded dental implant system.
Merging Proprietary Biomedical Materials with Human Cell Biology
12

12. Near-term Regulatory Clearance
• Ti-FOAM™ NT Threaded Implant System is fully developed
• U.S. – Class 2 device following 510k Pre-market Notification
application process (demonstrate equivalence with approved
device – clinical trials NOT required)
• Completed:
• Development and optimization of design
• Validation of performance
• Optimized fabrication process
• Required:
Preparation of Application (estimate)
60 days
FDA Clearance Time for Dental Implant (allows for marketing)
90 days
ESTIMATED TIME TO “APPROVAL”
The EVOLUTION of
150 days

13. Merging Proprietary Biomedical Materials with Human Cell Biology
online worldwide ordering system
offer a low cost end user dental implant
numerous up sell possibilities
Focus on emerging markets
Revenue Sources
• Dental Implant Systems
• Attachments
• Surgical Instrumentation
• Biologics
• Education and Practice growth strategies
2/11/2014
14

14. POROUS TITANIUM SCAFFOLD

SEM View of the
TI-FOAM™
Threaded Dental
Implant
NANOTECH GROWTH INDUCERS
2/11/2014
15

15. 



TI-FOAM™ Full Foam Design dental implant
(designed and tested – undeveloped)
TI-FOAM™ Full Foam threaded dental implant
Biologics –graft material
Hip, knee and shoulder designs
Open Cell BioMed Merging Proprietary Biomedical Materials with Human Cell Biology
2/11/2014
16

16. Merging Proprietary Biomedical Materials with Human Cell Biology
Getting the word out
Build a Doctor sales force by making their
practice a Center for Excellence.
Focus on the Ultimate Decision Makers
“Patients” Through web based and viral
marketing campaigns t
Trade Show exhibits and Conferences are the
most common and effective forms of getting
information and awareness to the Doctors
that are using dental implants already or may
want to use our product
2/11/2014
17

17. Direct To Consumer Advertising is the
future of Healthcare marketing

Direct to consumer multi-media blitz –
emphasis on Ti Foam™ ‘s patient
benefits/Patients wants: Fast
procedures, Minimally invasive
procedures, Long lasting results and
Good aesthetics

Medical, pharmaceutical and now
dental advertising is on the increase

Consumer awareness of dental
implants is increasing

Patients seek more information
regarding treatment and they will
increasingly use the resources of the
internet and social media
2/11/2014
18

18. Merging Proprietary
Biomedical Materials with
Human Cell Biology
2/11/2014
Mislav Pavelic Founder/CEO, DDS, FICOI
25 years of Industry experience with over 10,000 real world surgeries
2 previous successful startups with industry buyouts
William Simmons COO 30 years operational experience in
manufacturing and design of dental implants
Stefan Kim VP Marketing /Sales New Media Guru
Ragan Mengal CFO 15 years in finance
19

19. 




Capital expenditures
Regulatory,
documentation
/administration
Operations
Marketing
R&D
.
Open Cell BioMed Merging Proprietary Biomedical Materials with Human Cell Biology
2/11/2014
20

20. Seeking Funding to commercialize the product line
Series A funding of 1.5 million -preferred shares
 Distributor – selling rights sold per area – sales
Seeking $1.5 million
FDA & split Canada Marketing Applications 20%
Health on commission basis
$500,000
PatentJoint Ventures – negotiable - M&A
$100,000
 expenses (incl. additional applications)

Packaging and labeling
$200,000
Marketing and Sales
$200,000
Salaries and Administration
$500,000
2/11/2014
21